Loading
A phase 3 trial of Azacitidine, Venetoclax, Decitabine and Cytarabine in acute myeloid leukaemia, run by Sellas Life Sciences Group, active and no longer recruiting.
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 is a phase 3 interventional study registered as NCT04229979 by Sellas Life Sciences Group, with 127 participants enrolled, started 2021-02-08 and due to reach its primary completion in 2025-12. Interventions recorded: Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine and GM-CSF.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Galena Biopharma, Azacitidine, Venetoclax and the tag pipeline.
Shares Cytarabine, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Cytarabine, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Decitabine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Decitabine, Azacitidine, Venetoclax and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/